BioMagnetic Solutions Overview
- Year Founded
-
2012

- Status
-
Acquired/Merged
- Employees
-
20

- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
6
BioMagnetic Solutions General Information
Description
Developer of immunomagnetic cell separation systems intended to serve clinicians, biomedical scientists and CAR-T cell & gene therapy product manufacturers. The company's system utilizes a closed immunomagnetic platform that uses nano-magnetic ferrofluids which increase the speed, ease of use, and flexibility of CAR-T Cell and Gene Therapy (CGT) product manufacture, enabling users to deliver reliable CGT performance.
Contact Information
Website
www.biomagneticsolutions.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Primary Office
- 3058 Research Drive
- State College, PA 16801
- United States
+1 (833) 000-0000
BioMagnetic Solutions Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
BioMagnetic Solutions Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of immunomagnetic cell separation systems intended to serve clinicians, biomedical scientists and CAR-T cell &
Biotechnology
State College, PA
20
As of 2023
00.00
000000000000
00.00
BioMagnetic Solutions Competitors (2)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
StemCell Technologies | Private Debt Financed | Vancouver, Canada | 0000 | 000.00 | 00000000. 00 | 000.00 |
00000000 000000 | Private Debt Financed | Bergisch Gladbach, Germany | 0000 | 000000000 |
BioMagnetic Solutions Patents
BioMagnetic Solutions Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3180451-A1 | Compositions and methods for negative selection of naive t and b cells with a single antibody | Pending | 28-May-2020 | 000000000 | |
EP-4157989-A1 | Compositions and methods for negative selection of naive t and b cells with a single antibody | Pending | 28-May-2020 | 000000000 | |
US-20230220325-A1 | Compositions and methods for negative selection of naive t and b cells with a single antibody | Pending | 28-May-2020 | 000000000 | |
AU-2020378322-A1 | An improved large scale immunomagnetic separation device | Pending | 05-Nov-2019 | 000000000 | |
CA-3159919-A1 | An improved large scale immunomagnetic separation device | Pending | 05-Nov-2019 | B03C1/005 |
BioMagnetic Solutions Executive Team (2)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Paul Liberti Ph.D | Co-Founder, Chief Executive Officer, Chief Scientific Officer & President | ||
Ted Liberti Ph.D | Founder & Chief Commercial Officer |
BioMagnetic Solutions Signals
BioMagnetic Solutions Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|